327 related articles for article (PubMed ID: 31101939)
1. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis.
Safary A; Akbarzadeh Khiavi M; Omidi Y; Rafi MA
Cell Mol Life Sci; 2019 Sep; 76(17):3363-3381. PubMed ID: 31101939
[TBL] [Abstract][Full Text] [Related]
2. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
4. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
Critchley BJ; Gaspar HB; Benedetti S
Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
[TBL] [Abstract][Full Text] [Related]
5. Mucopolysaccharidoses and the blood-brain barrier.
Sahin O; Thompson HP; Goodman GW; Li J; Urayama A
Fluids Barriers CNS; 2022 Sep; 19(1):76. PubMed ID: 36117162
[TBL] [Abstract][Full Text] [Related]
6. Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses.
Fachel FNS; Frâncio L; Poletto É; Schuh RS; Teixeira HF; Giugliani R; Baldo G; Matte U
Adv Drug Deliv Rev; 2022 Dec; 191():114616. PubMed ID: 36356930
[TBL] [Abstract][Full Text] [Related]
7. Current and potential therapeutic strategies for mucopolysaccharidoses.
Noh H; Lee JI
J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
[TBL] [Abstract][Full Text] [Related]
8. Therapies for neurological disease in the mucopolysaccharidoses.
Anson DS; McIntyre C; Byers S
Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
[TBL] [Abstract][Full Text] [Related]
9. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.
Sato Y; Okuyama T
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936354
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
[TBL] [Abstract][Full Text] [Related]
11. Possible strategies to cross the blood-brain barrier.
Bellettato CM; Scarpa M
Ital J Pediatr; 2018 Nov; 44(Suppl 2):131. PubMed ID: 30442184
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapies: what is the best option?
Safary A; Akbarzadeh Khiavi M; Mousavi R; Barar J; Rafi MA
Bioimpacts; 2018; 8(3):153-157. PubMed ID: 30211074
[TBL] [Abstract][Full Text] [Related]
13. Current and Emerging Therapies for Mucopolysaccharidoses.
Lagler FB
Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968
[TBL] [Abstract][Full Text] [Related]
14. New prospects for the treatment of lysosomal storage diseases.
Schiffmann R; Brady RO
Drugs; 2002; 62(5):733-42. PubMed ID: 11929328
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for the treatment of mucopolysaccharidoses.
Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
[TBL] [Abstract][Full Text] [Related]
16. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
17. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS.
Giugliani R; Vairo F; Kubaski F; Poswar F; Riegel M; Baldo G; Saute JA
Lancet Child Adolesc Health; 2018 Jan; 2(1):56-68. PubMed ID: 30169196
[TBL] [Abstract][Full Text] [Related]
18. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
19. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology applied to treatment of mucopolysaccharidoses.
Schuh RS; Baldo G; Teixeira HF
Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
